Patents by Inventor Patricia A. McKernan

Patricia A. McKernan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030161811
    Abstract: Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus. IL-20 can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.
    Type: Application
    Filed: December 17, 2002
    Publication date: August 28, 2003
    Inventors: Yasmin A. Chandrasekher, Patricia A. McKernan
  • Patent number: 6395740
    Abstract: Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the present invention are also useful in libraries and in assays for the determination of calcitonin receptor activity.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: May 28, 2002
    Assignee: ZymoGenetics, Inc.
    Inventors: Nand Baindur, Virender Labroo, Steven Stroop, Stephanie Beigel, Theresa Martinez, Charles R. Petrie, Mark W. Orme, Patricia A. Mckernan, Emma E. Moore
  • Patent number: 6391917
    Abstract: Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: May 21, 2002
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles R. Petrie, Patricia A. McKernan, Emma E. Moore, John M. Ostresh, Jean-Philippe Meyer, Richard A. Houghten, Clemencia Pinilla
  • Patent number: 6376476
    Abstract: Various embodiments of statin compounds are shown to enhance the formation of bone and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: April 23, 2002
    Assignees: ZymoGenetics Corporation, OsteoScreen, Inc.
    Inventors: Shirley R. Gasper, Robert R. West, Theresa Martinez, Kirk G. Robbins, Patricia A. McKernan, Nand Baindur, Virender M. Labroo, Gregory R. Mundy
  • Publication number: 20010034364
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: May 3, 2001
    Publication date: October 25, 2001
    Inventors: Shirley R. Gasper, Robert R. West, Theresa Martinez, Kirk G. Robbins, Patricia A. McKernan, Nand Baindur, Virender M. Labroo, Gregory R. Mundy
  • Patent number: 6255351
    Abstract: Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: July 3, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles R. Petrie, Patricia A. McKernan, Emma E. Moore, John M. Ostresh, Jean-Philippe Meyer, Richard A. Houghten, Clemencia Pinilla
  • Patent number: 6221913
    Abstract: Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: April 24, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles R. Petrie, Patricia A. McKernan, Emma E. Moore, John M. Ostresh, Jean-Philippe Meyer, Richard A. Houghten, Clemencia Pinilla
  • Patent number: 6124299
    Abstract: Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the present invention are also useful in libraries and in assays for the determination of calcitonin receptor activity.
    Type: Grant
    Filed: February 23, 1998
    Date of Patent: September 26, 2000
    Assignee: ZymoGenetics, Inc.
    Inventors: Nand Baindur, Virender Labroo, Steven Stroop, Stephanie Beigel, Theresa Martinez, Charles R. Petrie, Mark W. Orme, Patricia A. McKernan, Emma E. Moore
  • Patent number: 6080779
    Abstract: Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6 C;Y represents one or more carbocyclic or heterocyclic rings; when two or more rings are present in Y, they may optionally be fused; andR' represents a cation, H or a substituted or unsubstituted alkyl group of 1-6 C; andthe dotted lines represent optional .pi.-bonds,promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation. These compounds can be used in combination with other bone growth-promoting compounds and/or estrogens and/or bisphosphonates for this purpose.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: June 27, 2000
    Assignees: OsteoScreen, Inc., ZymoGenetics Corporation
    Inventors: Shirley R. Gasper, Robert R. West, Theresa Martinez, Kirk G. Robbins, Patricia A. McKernan, Nand Baindur, Virender M. Labroo, Gregory R. Mundy
  • Patent number: 6022887
    Abstract: Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C;Y represents one or more carbocyclic or heterocyclic rings; when two or more rings are present in Y, they may optionally be fused; andR' represents a cation, H or a substituted or unsubstituted alkyl group of 1-6C; andthe dotted lines represent optional .pi.-bonds,promote bone formation and are thus usefull in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: February 8, 2000
    Assignees: OsteoScreen, Inc., ZymoGenetics Corporation
    Inventors: Shirley R. Gasper, Robert R. West, Theresa Martinez, Kirk G. Robbins, Patricia A. McKernan, Nand Baindur, Virender M. Labroo
  • Patent number: 5698521
    Abstract: The invention provides isolated, biologically active native calcitonin mimetics and related methods. These small 16 and 17 amino acid proteins mimic the interaction of calcitonin on its receptor, and also exhibit bone resorptive inhibiting activity.
    Type: Grant
    Filed: April 4, 1995
    Date of Patent: December 16, 1997
    Assignee: ZymoGenetics, Inc.
    Inventors: Patricia A. McKernan, Lennie Chen, Charles Petrie, James Piggott, Robert R. West, Shirley Gasper, Colin Lellis
  • Patent number: 5677334
    Abstract: Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response pathway. The glucagon antagonists may be used within therapeutic compositions to treat disease states associate with elevated glucose levels, including diabetes and hyperglycemia. The present invention also discloses a biologically pure culture of ATCC accession number 74200, as well as methods relating to the production of glucagon antagonists by cultivating the same in a nutrient medium and recovering the glucagon antagonist therefrom.
    Type: Grant
    Filed: September 11, 1995
    Date of Patent: October 14, 1997
    Assignee: ZymoGenetics, Inc.
    Inventors: Robert R. West, Virender Labroo, James R. Piggott, Robert A. Smith, Patricia A. McKernan
  • Patent number: 5508304
    Abstract: Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response pathway. The glucagon antagonists may be used within therapeutic compositions to treat disease states associate with elevated glucose levels, including diabetes and hyperglycemia. The present invention also discloses a biologically pure culture of ATCC accession number 74200, as well as methods relating to the production of glucagon antagonists by cultivating the same in a nutrient medium and recovering the glucagon antagonist therefrom.
    Type: Grant
    Filed: August 10, 1994
    Date of Patent: April 16, 1996
    Assignee: ZymoGenetics, Inc.
    Inventors: Robert R. West, Virender Labroo, James R. Piggott, Robert A. Smith, Patricia A. McKernan